Analyst consensus rating
Zenas BioPharma Analyst Rating: none
Direct answer
Zenas BioPharma's consensus rating is none.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $47.00.
Forecast evidence checked September 4, 2026.
Get free Zenas BioPharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $32.92
- Average price target
- $47.00
- High price target
- $59.00
- Low price target
- $32.00
- Low target gap
- -2.8%
- Target upside
- +42.8%
- High target gap
- +79.2%
- Target range width
- 82%
- Consensus rating
- none
- Analysts
- 8
- Evidence date
- September 4, 2026
- Valid through
- September 11, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Zenas BioPharma?
Zenas BioPharma has a verified none consensus. The same dataset has an average price target of $47.00.
How far are Zenas BioPharma's low and high targets from the recorded price?
The low target implies -2.8%, while the high target implies +79.2%.
How many analysts are included in Zenas BioPharma's consensus?
The verified consensus includes 8 analysts.
How is Zenas BioPharma's target upside or downside calculated?
The average target of $47.00 is divided by the recorded price of $32.92, then one is subtracted to produce +42.8%. This does not guarantee a future return.
When was Zenas BioPharma's analyst forecast verified?
The data was verified on 2026-09-04. The dataset is valid through 2026-09-11.